finally some good news for NBIX...long time coming
SAN DIEGO, April 5, 2011 /PRNewswire/ --Neurocrine Biosciences, Inc. (NASDAQ:NBIX - News) announced today that it has completed the dosing and preliminary assessment of the initial cohort of Tardive Dyskinesia patients using its proprietary...